Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Intuitive Surgical Inc(ISRG)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ISRG
10/02/2026: ISRG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Intuitive Surgical is a specialized medical technology company known for its da Vinci robotic surgical systems, which have a leading position in minimally invasive surgery. Its core strength lies in a highly profitable, recurring revenue model built on proprietary instruments and maintenance services. The company's main growth story centers on the global expansion of robotic-assisted procedures and the rollout of its next-generation platforms, such as the da Vinci 5. Investors must monitor risks related to rising competition from major medical device players, premium stock valuations, and hospital spending cycles. It is a long-term play that may best suit growth-oriented investors looking for exposure to clinical innovation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth sector with consistent procedure volume increases. |
| Momentum investor | Strong fit while signal remains positive | The stock frequently demonstrates strong price trends reflecting consistent operational success. |
| Value investor | Mixed fit | The stock often trades at a premium valuation reflecting its high-quality market position. |
| Dividend investor | Weak fit | Intuitive Surgical does not pay a dividend. |
| Low-risk investor | Mixed fit | While the business is high quality, the stock can experience significant volatility characteristic of high-growth technology equities. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | High-growth multiples often lead to stock price sensitivity regarding earnings results. |
| Valuation risk | High | The stock's premium valuation requires consistent execution to maintain its current price levels. |
| Competition risk (Robotics & Medtech) | Medium | Large incumbents like JNJ and MDT are investing heavily to challenge Intuitive's market share. |
| Business quality | Strong | The company holds a strong, entrenched market position with significant recurring revenue. |
| Dividend income | Low / none | Investors should not look to this stock for regular income. |
| Execution risk | Medium | The company must continue to innovate with platforms like da Vinci 5 to remain ahead of new competitors. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 5.95% | Avg. Invested days 51 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 143.76B USD | Price to earnings Ratio 46.71 | 1Y Target Price 476.34 |
Price to earnings Ratio 46.71 | 1Y Target Price 476.34 | ||
Volume (30-day avg) 2.2M shares | Beta 1.47 | 52 Weeks Range 328.57 - 603.88 | Updated Date 10/02/2026 |
52 Weeks Range 328.57 - 603.88 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 8.59 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Systems | Sale of da Vinci and Ion surgical robotic systems. | This provides large, upfront revenue per sale but is cyclical. |
| Instruments and Accessories | Single-use surgical instruments required for every procedure. | This is the core recurring revenue engine driving long-term stability. |
| Services | System maintenance, training, and clinical support contracts. | Steady revenue that builds sticky relationships with hospital customers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 46.71 | Forward PE 33.33 | Enterprise Value 136.83B | Price to Sales(TTM) 13.03 |
Enterprise Value 136.83B | Price to Sales(TTM) 13.03 | ||
Enterprise Value to Revenue 12.4 | Enterprise Value to EBITDA 32.23 | Shares Outstanding 358.28M | Shares Floating 351.21M |
Shares Outstanding 358.28M | Shares Floating 351.21M | ||
Percent Insiders 0.51 | Percent Institutions 89.44 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
News (Last Updated: 10/02/2026)
About Intuitive Surgical Inc
Exchange NASDAQ | Headquarters Sunnyvale, CA, United States | ||
IPO Launch date 2000-06-13 | CEO & Director Mr. David J. Rosa | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 17021 | Website https://www.intuitive.com |
Full time employees 17021 | Website https://www.intuitive.com | ||
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.